DAAs and Protease-Inhibitors Improving Standard of Care for HCV Treatment; Survival Rates Greater Than 90% Reported, According to BCC Research

June 19, 2015

Wellesley, Mass., June 19, 2015 – An aging population, increasing global prevalence of liver disorders, and high unmet needs existing in liver cancer are driving the market for liver disease treatments.  BCC Research reveals in its new report that highly priced new therapeutic options such as direct-acting antiviral (DAA) have improved the standard of treatment of hepatitis C virus (HCV) disease, a leading cause of liver-related morbidity and mortality.

The global liver diseases therapeutics market totaled nearly $24.5 billion in 2014 and is projected to near $33.8 billion by 2019, registering a five-year compound annual growth rate (CAGR) of 6.7%. Among segments, the U.S. totaled almost $9.1 billion in 2014 and should total $11.9 billion by 2019, reflecting a CAGR of 5.6%. Rest of the world as a segment reached nearly $7.7 billion in 2014 and should reach $11.4 billion by 2019, posting a CAGR of 8.1%.

In 2013, hepatitis was the largest segment in global sales by disease type, followed by the chronic liver disease market. During the forecast period, the hepatocellular carcinoma segment is projected to have the highest CAGR rate, and by 2019 should supplant the chronic liver disease market as the second- largest market.

The past 25 years of medical research in liver disease has resulted in major improvements in patient survival and quality of life. Presently, numerous products at various stages of developments have the potential to bring more profound and important changes in the liver disease treatment modality. The launch of DAAs in the past few years has improved the standard of treatment of hepatitis C virus (HCV) disease. These therapies not only have enhanced tolerability, shorter treatment duration and less intensive monitoring requirements, but also have higher cure rates than interferon (IFN) therapies.

“The introduction of DAAs and protease-inhibitors (PIS) after 2011 has contributed to the changing scenario of standard of care for HCV treatment,” says BCC Research analyst Yogita Zutshi. “The 2014 launch of Sovaldi (Sofosbuvir) and Olysio (Simeprevir) signaled the start of highly efficacious anti-HCV therapeutic regimens with significantly improved SVR rates.”

Liver Disease Treatments: The Global Market (PHM057C) examines the areas of growth in the liver disease drug market from the point of view of both manufacturers and users. The report details the different categories of liver disease drugs and the various types of liver disease segmented by market share. The strategies and the prospects of the current market also are discussed.

Editors and reporters who wish to speak with the analyst should contact Steven Cumming at steven.cumming@bccresearch.com.

Liver Disease Treatments: The Global Market( PHM057C )
Publish Date: Jun 2015    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.